A detailed history of Bayesian Capital Management, LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bayesian Capital Management, LP holds 8,800 shares of CRSP stock, worth $447,392. This represents 0.05% of its overall portfolio holdings.

Number of Shares
8,800
Previous 6,200 41.94%
Holding current value
$447,392
Previous $334,000 23.65%
% of portfolio
0.05%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$44.62 - $62.75 $116,012 - $163,150
2,600 Added 41.94%
8,800 $413,000
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $1.78 Million - $2.37 Million
-34,800 Reduced 84.88%
6,200 $334,000
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $2.49 Million - $3.65 Million
41,000 New
41,000 $2.79 Million
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $788,067 - $1.23 Million
18,129 New
18,129 $1.02 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $501,318 - $840,050
12,792 New
12,792 $519,000
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $216,149 - $369,150
-5,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$53.19 - $79.24 $265,950 - $396,200
5,000 New
5,000 $314,000
Q2 2020

Aug 14, 2020

SELL
$38.5 - $76.05 $238,700 - $471,510
-6,200 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$33.68 - $62.53 $208,816 - $387,686
6,200 New
6,200 $263,000
Q3 2019

Nov 13, 2019

SELL
$40.99 - $52.56 $188,308 - $241,460
-4,594 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$35.45 - $48.2 $173,917 - $236,469
-4,906 Reduced 51.64%
4,594 $216,000
Q1 2019

May 14, 2019

BUY
$28.02 - $40.87 $266,190 - $388,265
9,500 New
9,500 $339,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.